Yogesh S Sanghvi

This inventor holds 38 USPTO granted patents, primarily in Oligonucleotide Chemistry. Top assignees: Isis Pharmaceuticals, Inc., Other. Active years: 1993-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yogesh S Sanghvi. Retrieved from https://idiyas.com/inventor/yogesh-s-sanghvi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38

% Patents Active = 94.7

Average Co-Inventor Count = 2.6

ph-index = 21

Forward Citations = 5,748(Granted Patents)

Location History:

Carlsbad, CA (US) (1995 - 1999)
San Marcos, CA (US) (1993 - 2005)
Encinitas, CA (US) (1998 - 2005)

Company Filing History:

36 out of 1,035

Isis Pharmaceuticals, Inc.

patents

2 out of 834,513

Other

patents

Years Active: 1993-2005

Loading Chart...

Areas of Expertise:

Oligonucleotide

Modified Analogs

Synthesis Process

Chiral Linkages

Nucleosides

Oligonucleoside

Pyrimidines

Activators

Antisense Inhibition

Heteroatomic Linkages

Building Blocks

Triarylmethyl Halide

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6900301 - Backbone modified oligonucleotide analogues (2005-05-31),

2. 6867294 - Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages (2005-03-15),

3. 6822089 - Preparation of deoxynucleosides (2004-11-23),

4. 6809195 - Process for the preparation of oligonucleotides (2004-10-26),

5. 6800751 - Reagent and process for protecting nucleoside hydroxyl groups (2004-10-05),

6. 6677120 - Building blocks for the solution phase synthesis of oligonucleotides (2004-01-13),

7. 6642367 - Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom (2003-11-04),

8. 6541626 - Process for selective N-acylation of purine nucleosides (2003-04-01),

9. 6359124 - Antisense inhibition of ras gene with chimeric and alternating oligonucleotides (2002-03-19),

10. 6274725 - Activators for oligonucleotide synthesis (2001-08-14),

11. 6271357 - Oligonucleotide mimics having nitrogen-containing linkages (2001-08-07),

12. 6239220 - Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis (2001-05-29),

13. 6222025 - Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom (2001-04-24),

14. 6214551 - Oligonucleoside linkages containing adjacent nitrogen atoms (2001-04-10),

15. 6166197 - Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 (2000-12-25),

Title: The Innovative Journey of Yogesh S Sanghvi

Introduction: Yogesh S Sanghvi, a talented inventor based in Encinitas, CA, has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: Sanghvi's latest patents include a cutting-edge wearable device that monitors vital signs in real-time, a revolutionary software for data encryption, and a solar-powered irrigation system for sustainable agriculture.

Career Highlights: With a career spanning over two decades, Sanghvi has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing innovative solutions. He has received numerous accolades for his work, including the prestigious Inventor of the Year award.

Collaborations: Throughout his career, Sanghvi has collaborated with leading tech companies, research institutions, and universities to bring his inventions to life. His ability to work seamlessly with multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Yogesh S Sanghvi's relentless passion for innovation and his commitment to pushing the boundaries of technology make him a true pioneer in the world of inventions. His remarkable contributions continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]